nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—EPHA7—cerebellum—intracranial aneurysm	0.0066	0.0154	CbGeAlD
Crizotinib—TEK—artery—intracranial aneurysm	0.00657	0.0154	CbGeAlD
Crizotinib—ROS1—brain—intracranial aneurysm	0.00586	0.0137	CbGeAlD
Crizotinib—SRC—artery—intracranial aneurysm	0.00584	0.0136	CbGeAlD
Crizotinib—MET—brainstem—intracranial aneurysm	0.00551	0.0129	CbGeAlD
Crizotinib—EPHA7—brain—intracranial aneurysm	0.00536	0.0125	CbGeAlD
Crizotinib—IKBKE—cerebellum—intracranial aneurysm	0.005	0.0117	CbGeAlD
Crizotinib—NTRK1—midbrain—intracranial aneurysm	0.0049	0.0114	CbGeAlD
Crizotinib—PRKD1—medulla oblongata—intracranial aneurysm	0.00462	0.0108	CbGeAlD
Crizotinib—TYRO3—brainstem—intracranial aneurysm	0.0045	0.0105	CbGeAlD
Crizotinib—IGF1R—brainstem—intracranial aneurysm	0.00433	0.0101	CbGeAlD
Crizotinib—LIMK1—midbrain—intracranial aneurysm	0.00416	0.00973	CbGeAlD
Crizotinib—DSTYK—midbrain—intracranial aneurysm	0.00396	0.00925	CbGeAlD
Crizotinib—MAP3K12—brainstem—intracranial aneurysm	0.00383	0.00895	CbGeAlD
Crizotinib—STK35—brainstem—intracranial aneurysm	0.00375	0.00877	CbGeAlD
Crizotinib—DCLK1—medulla oblongata—intracranial aneurysm	0.00336	0.00786	CbGeAlD
Crizotinib—EPHA4—brainstem—intracranial aneurysm	0.00334	0.00781	CbGeAlD
Crizotinib—PRKD1—cerebellum—intracranial aneurysm	0.00327	0.00763	CbGeAlD
Crizotinib—LIMK1—cerebellum—intracranial aneurysm	0.00322	0.00753	CbGeAlD
Crizotinib—EPHA5—medulla oblongata—intracranial aneurysm	0.00314	0.00734	CbGeAlD
Crizotinib—ALK—medulla oblongata—intracranial aneurysm	0.00314	0.00734	CbGeAlD
Crizotinib—FER—medulla oblongata—intracranial aneurysm	0.00314	0.00734	CbGeAlD
Crizotinib—PRKD3—cerebellum—intracranial aneurysm	0.00314	0.00733	CbGeAlD
Crizotinib—DCLK1—midbrain—intracranial aneurysm	0.00308	0.00719	CbGeAlD
Crizotinib—DSTYK—cerebellum—intracranial aneurysm	0.00306	0.00716	CbGeAlD
Crizotinib—CASK—cerebellum—intracranial aneurysm	0.00299	0.007	CbGeAlD
Crizotinib—MAP4K2—medulla oblongata—intracranial aneurysm	0.00298	0.00695	CbGeAlD
Crizotinib—NEK9—brain—intracranial aneurysm	0.00291	0.0068	CbGeAlD
Crizotinib—MAPK7—cerebellum—intracranial aneurysm	0.0029	0.00678	CbGeAlD
Crizotinib—EPHA8—cerebellum—intracranial aneurysm	0.00287	0.00671	CbGeAlD
Crizotinib—EPHA5—midbrain—intracranial aneurysm	0.00287	0.00671	CbGeAlD
Crizotinib—ALK—midbrain—intracranial aneurysm	0.00287	0.00671	CbGeAlD
Crizotinib—FER—midbrain—intracranial aneurysm	0.00287	0.00671	CbGeAlD
Crizotinib—TESK1—medulla oblongata—intracranial aneurysm	0.00284	0.00663	CbGeAlD
Crizotinib—MAP4K2—midbrain—intracranial aneurysm	0.00272	0.00636	CbGeAlD
Crizotinib—MET—cerebellum—intracranial aneurysm	0.00271	0.00634	CbGeAlD
Crizotinib—MAP3K12—medulla oblongata—intracranial aneurysm	0.00267	0.00624	CbGeAlD
Crizotinib—ACVR1—medulla oblongata—intracranial aneurysm	0.00267	0.00624	CbGeAlD
Crizotinib—PRKD1—brain—intracranial aneurysm	0.00265	0.0062	CbGeAlD
Crizotinib—CDK7—cerebellum—intracranial aneurysm	0.00263	0.00614	CbGeAlD
Crizotinib—SIK2—brain—intracranial aneurysm	0.00262	0.00611	CbGeAlD
Crizotinib—LIMK1—brain—intracranial aneurysm	0.00262	0.00611	CbGeAlD
Crizotinib—TAOK2—cerebellum—intracranial aneurysm	0.00261	0.00609	CbGeAlD
Crizotinib—TESK1—midbrain—intracranial aneurysm	0.00259	0.00606	CbGeAlD
Crizotinib—TAOK3—brainstem—intracranial aneurysm	0.00255	0.00596	CbGeAlD
Crizotinib—PRKD3—brain—intracranial aneurysm	0.00255	0.00596	CbGeAlD
Crizotinib—ACVR1B—cerebellum—intracranial aneurysm	0.00251	0.00586	CbGeAlD
Crizotinib—DSTYK—brain—intracranial aneurysm	0.00249	0.00582	CbGeAlD
Crizotinib—ACVR1—midbrain—intracranial aneurysm	0.00244	0.0057	CbGeAlD
Crizotinib—MAP3K12—midbrain—intracranial aneurysm	0.00244	0.0057	CbGeAlD
Crizotinib—LTK—brain—intracranial aneurysm	0.00243	0.00568	CbGeAlD
Crizotinib—CASK—brain—intracranial aneurysm	0.00243	0.00568	CbGeAlD
Crizotinib—RIPK2—medulla oblongata—intracranial aneurysm	0.00241	0.00564	CbGeAlD
Crizotinib—JAK3—cerebellum—intracranial aneurysm	0.00239	0.00559	CbGeAlD
Crizotinib—STK35—midbrain—intracranial aneurysm	0.00239	0.00559	CbGeAlD
Crizotinib—DCLK1—cerebellum—intracranial aneurysm	0.00238	0.00556	CbGeAlD
Crizotinib—MAPK7—brain—intracranial aneurysm	0.00236	0.0055	CbGeAlD
Crizotinib—STK4—cerebellum—intracranial aneurysm	0.00235	0.00549	CbGeAlD
Crizotinib—EPHA4—medulla oblongata—intracranial aneurysm	0.00233	0.00545	CbGeAlD
Crizotinib—EPHA8—brain—intracranial aneurysm	0.00233	0.00545	CbGeAlD
Crizotinib—FES—brain—intracranial aneurysm	0.00233	0.00545	CbGeAlD
Crizotinib—BMP2K—midbrain—intracranial aneurysm	0.0023	0.00538	CbGeAlD
Crizotinib—TBK1—medulla oblongata—intracranial aneurysm	0.00224	0.00523	CbGeAlD
Crizotinib—TYK2—medulla oblongata—intracranial aneurysm	0.00222	0.0052	CbGeAlD
Crizotinib—EPHA5—cerebellum—intracranial aneurysm	0.00222	0.00519	CbGeAlD
Crizotinib—TYRO3—cerebellum—intracranial aneurysm	0.00222	0.00519	CbGeAlD
Crizotinib—FER—cerebellum—intracranial aneurysm	0.00222	0.00519	CbGeAlD
Crizotinib—MET—brain—intracranial aneurysm	0.00221	0.00515	CbGeAlD
Crizotinib—RIPK2—midbrain—intracranial aneurysm	0.00221	0.00515	CbGeAlD
Crizotinib—TNK1—cerebellum—intracranial aneurysm	0.0022	0.00514	CbGeAlD
Crizotinib—BMPR1B—cerebellum—intracranial aneurysm	0.00218	0.00508	CbGeAlD
Crizotinib—RPS6KB1—medulla oblongata—intracranial aneurysm	0.00215	0.00503	CbGeAlD
Crizotinib—TNK2—cerebellum—intracranial aneurysm	0.00213	0.00499	CbGeAlD
Crizotinib—IGF1R—cerebellum—intracranial aneurysm	0.00213	0.00499	CbGeAlD
Crizotinib—AXL—medulla oblongata—intracranial aneurysm	0.00213	0.00498	CbGeAlD
Crizotinib—CDK7—brain—intracranial aneurysm	0.00213	0.00498	CbGeAlD
Crizotinib—TAOK2—brain—intracranial aneurysm	0.00212	0.00494	CbGeAlD
Crizotinib—MAP4K2—cerebellum—intracranial aneurysm	0.0021	0.00492	CbGeAlD
Crizotinib—STK3—cerebellum—intracranial aneurysm	0.00208	0.00485	CbGeAlD
Crizotinib—TIE1—cerebellum—intracranial aneurysm	0.00208	0.00485	CbGeAlD
Crizotinib—SLK—medulla oblongata—intracranial aneurysm	0.00205	0.0048	CbGeAlD
Crizotinib—PTK2—midbrain—intracranial aneurysm	0.00205	0.00478	CbGeAlD
Crizotinib—TBK1—midbrain—intracranial aneurysm	0.00205	0.00478	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—intracranial aneurysm	0.00204	0.00476	CbGeAlD
Crizotinib—EPHA3—brain—intracranial aneurysm	0.00204	0.00476	CbGeAlD
Crizotinib—ACVR1B—brain—intracranial aneurysm	0.00204	0.00476	CbGeAlD
Crizotinib—TYK2—midbrain—intracranial aneurysm	0.00203	0.00475	CbGeAlD
Crizotinib—JAK2—medulla oblongata—intracranial aneurysm	0.00202	0.00473	CbGeAlD
Crizotinib—IRAK1—midbrain—intracranial aneurysm	0.00201	0.00469	CbGeAlD
Crizotinib—TESK1—cerebellum—intracranial aneurysm	0.00201	0.00469	CbGeAlD
Crizotinib—RPS6KB1—midbrain—intracranial aneurysm	0.00197	0.0046	CbGeAlD
Crizotinib—MERTK—cerebellum—intracranial aneurysm	0.00195	0.00456	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—intracranial aneurysm	0.00195	0.00456	CbGeAlD
Crizotinib—TEK—medulla oblongata—intracranial aneurysm	0.00195	0.00456	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—intracranial aneurysm	0.00195	0.00456	CbGeAlD
Crizotinib—AXL—midbrain—intracranial aneurysm	0.00195	0.00456	CbGeAlD
Crizotinib—EPHA6—brain—intracranial aneurysm	0.00194	0.00454	CbGeAlD
Crizotinib—JAK3—brain—intracranial aneurysm	0.00194	0.00454	CbGeAlD
Crizotinib—DCLK1—brain—intracranial aneurysm	0.00193	0.00452	CbGeAlD
Crizotinib—PLK4—brain—intracranial aneurysm	0.00192	0.00449	CbGeAlD
Crizotinib—STK4—brain—intracranial aneurysm	0.00191	0.00446	CbGeAlD
Crizotinib—LIMK2—cerebellum—intracranial aneurysm	0.00191	0.00446	CbGeAlD
Crizotinib—NUAK2—cerebellum—intracranial aneurysm	0.0019	0.00444	CbGeAlD
Crizotinib—FLT3—cerebellum—intracranial aneurysm	0.00189	0.00441	CbGeAlD
Crizotinib—ACVR1—cerebellum—intracranial aneurysm	0.00189	0.00441	CbGeAlD
Crizotinib—MAP3K12—cerebellum—intracranial aneurysm	0.00189	0.00441	CbGeAlD
Crizotinib—SLK—midbrain—intracranial aneurysm	0.00188	0.00438	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—intracranial aneurysm	0.00186	0.00436	CbGeAlD
Crizotinib—EPHB4—midbrain—intracranial aneurysm	0.00186	0.00435	CbGeAlD
Crizotinib—STK35—cerebellum—intracranial aneurysm	0.00185	0.00432	CbGeAlD
Crizotinib—ALK—brain—intracranial aneurysm	0.0018	0.00422	CbGeAlD
Crizotinib—TYRO3—brain—intracranial aneurysm	0.0018	0.00422	CbGeAlD
Crizotinib—EPHA5—brain—intracranial aneurysm	0.0018	0.00422	CbGeAlD
Crizotinib—FER—brain—intracranial aneurysm	0.0018	0.00422	CbGeAlD
Crizotinib—ABL2—cerebellum—intracranial aneurysm	0.0018	0.00421	CbGeAlD
Crizotinib—YES1—medulla oblongata—intracranial aneurysm	0.0018	0.00421	CbGeAlD
Crizotinib—LYN—brain—intracranial aneurysm	0.00179	0.00419	CbGeAlD
Crizotinib—TNK1—brain—intracranial aneurysm	0.00179	0.00417	CbGeAlD
Crizotinib—MAP4K5—midbrain—intracranial aneurysm	0.00178	0.00417	CbGeAlD
Crizotinib—MAP3K3—midbrain—intracranial aneurysm	0.00178	0.00417	CbGeAlD
Crizotinib—TEK—midbrain—intracranial aneurysm	0.00178	0.00417	CbGeAlD
Crizotinib—BMP2K—cerebellum—intracranial aneurysm	0.00178	0.00416	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—intracranial aneurysm	0.00178	0.00416	CbGeAlD
Crizotinib—BMPR1B—brain—intracranial aneurysm	0.00177	0.00413	CbGeAlD
Crizotinib—MAP3K19—brain—intracranial aneurysm	0.00177	0.00413	CbGeAlD
Crizotinib—MAP4K1—brain—intracranial aneurysm	0.00177	0.00413	CbGeAlD
Crizotinib—ABL1—brainstem—intracranial aneurysm	0.00176	0.00412	CbGeAlD
Crizotinib—TNK2—brain—intracranial aneurysm	0.00173	0.00405	CbGeAlD
Crizotinib—IGF1R—brain—intracranial aneurysm	0.00173	0.00405	CbGeAlD
Crizotinib—PTK2B—cerebellum—intracranial aneurysm	0.00172	0.00402	CbGeAlD
Crizotinib—MAP4K2—brain—intracranial aneurysm	0.00171	0.00399	CbGeAlD
Crizotinib—RIPK2—cerebellum—intracranial aneurysm	0.00171	0.00399	CbGeAlD
Crizotinib—EPHB6—midbrain—intracranial aneurysm	0.0017	0.00398	CbGeAlD
Crizotinib—STK3—brain—intracranial aneurysm	0.00169	0.00394	CbGeAlD
Crizotinib—TIE1—brain—intracranial aneurysm	0.00169	0.00394	CbGeAlD
Crizotinib—EPHA4—cerebellum—intracranial aneurysm	0.00165	0.00385	CbGeAlD
Crizotinib—YES1—midbrain—intracranial aneurysm	0.00165	0.00385	CbGeAlD
Crizotinib—AURKA—brain—intracranial aneurysm	0.00164	0.00384	CbGeAlD
Crizotinib—TESK1—brain—intracranial aneurysm	0.00163	0.00381	CbGeAlD
Crizotinib—TAOK3—midbrain—intracranial aneurysm	0.00163	0.0038	CbGeAlD
Crizotinib—MAP3K2—cerebellum—intracranial aneurysm	0.00162	0.00378	CbGeAlD
Crizotinib—MERTK—brain—intracranial aneurysm	0.00159	0.0037	CbGeAlD
Crizotinib—PTK2—cerebellum—intracranial aneurysm	0.00158	0.0037	CbGeAlD
Crizotinib—TBK1—cerebellum—intracranial aneurysm	0.00158	0.0037	CbGeAlD
Crizotinib—TYK2—cerebellum—intracranial aneurysm	0.00157	0.00368	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—intracranial aneurysm	0.00156	0.00364	CbGeAlD
Crizotinib—IRAK1—cerebellum—intracranial aneurysm	0.00155	0.00363	CbGeAlD
Crizotinib—LIMK2—brain—intracranial aneurysm	0.00155	0.00362	CbGeAlD
Crizotinib—NUAK2—brain—intracranial aneurysm	0.00154	0.00361	CbGeAlD
Crizotinib—MAP3K12—brain—intracranial aneurysm	0.00153	0.00358	CbGeAlD
Crizotinib—ACVR1—brain—intracranial aneurysm	0.00153	0.00358	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—intracranial aneurysm	0.00152	0.00356	CbGeAlD
Crizotinib—AXL—cerebellum—intracranial aneurysm	0.00151	0.00352	CbGeAlD
Crizotinib—STK35—brain—intracranial aneurysm	0.0015	0.00351	CbGeAlD
Crizotinib—ABL2—brain—intracranial aneurysm	0.00146	0.00342	CbGeAlD
Crizotinib—SLK—cerebellum—intracranial aneurysm	0.00145	0.00339	CbGeAlD
Crizotinib—BMP2K—brain—intracranial aneurysm	0.00145	0.00338	CbGeAlD
Crizotinib—EPHB4—cerebellum—intracranial aneurysm	0.00144	0.00337	CbGeAlD
Crizotinib—JAK2—cerebellum—intracranial aneurysm	0.00143	0.00334	CbGeAlD
Crizotinib—CSF1R—midbrain—intracranial aneurysm	0.00142	0.00332	CbGeAlD
Crizotinib—PTK2B—brain—intracranial aneurysm	0.0014	0.00326	CbGeAlD
Crizotinib—RIPK2—brain—intracranial aneurysm	0.00139	0.00324	CbGeAlD
Crizotinib—MAP4K5—cerebellum—intracranial aneurysm	0.00138	0.00322	CbGeAlD
Crizotinib—MAP3K3—cerebellum—intracranial aneurysm	0.00138	0.00322	CbGeAlD
Crizotinib—TEK—cerebellum—intracranial aneurysm	0.00138	0.00322	CbGeAlD
Crizotinib—EPHA4—brain—intracranial aneurysm	0.00134	0.00313	CbGeAlD
Crizotinib—EPHB6—cerebellum—intracranial aneurysm	0.00132	0.00308	CbGeAlD
Crizotinib—MAP3K2—brain—intracranial aneurysm	0.00131	0.00307	CbGeAlD
Crizotinib—PTK2—brain—intracranial aneurysm	0.00129	0.00301	CbGeAlD
Crizotinib—TBK1—brain—intracranial aneurysm	0.00129	0.00301	CbGeAlD
Crizotinib—TYK2—brain—intracranial aneurysm	0.00128	0.00299	CbGeAlD
Crizotinib—YES1—cerebellum—intracranial aneurysm	0.00127	0.00298	CbGeAlD
Crizotinib—STK10—cerebellum—intracranial aneurysm	0.00126	0.00295	CbGeAlD
Crizotinib—IRAK1—brain—intracranial aneurysm	0.00126	0.00295	CbGeAlD
Crizotinib—TAOK3—cerebellum—intracranial aneurysm	0.00126	0.00294	CbGeAlD
Crizotinib—RPS6KB1—brain—intracranial aneurysm	0.00124	0.00289	CbGeAlD
Crizotinib—ABL1—medulla oblongata—intracranial aneurysm	0.00123	0.00287	CbGeAlD
Crizotinib—FGR—brain—intracranial aneurysm	0.00123	0.00287	CbGeAlD
Crizotinib—SRC—cerebellum—intracranial aneurysm	0.00123	0.00286	CbGeAlD
Crizotinib—AXL—brain—intracranial aneurysm	0.00123	0.00286	CbGeAlD
Crizotinib—SLK—brain—intracranial aneurysm	0.00118	0.00276	CbGeAlD
Crizotinib—EPHB4—brain—intracranial aneurysm	0.00117	0.00274	CbGeAlD
Crizotinib—JAK2—brain—intracranial aneurysm	0.00116	0.00272	CbGeAlD
Crizotinib—EPHA2—brain—intracranial aneurysm	0.00115	0.00268	CbGeAlD
Crizotinib—ABL1—midbrain—intracranial aneurysm	0.00112	0.00263	CbGeAlD
Crizotinib—TEK—brain—intracranial aneurysm	0.00112	0.00262	CbGeAlD
Crizotinib—MAP4K5—brain—intracranial aneurysm	0.00112	0.00262	CbGeAlD
Crizotinib—MAP3K3—brain—intracranial aneurysm	0.00112	0.00262	CbGeAlD
Crizotinib—CSF1R—cerebellum—intracranial aneurysm	0.0011	0.00257	CbGeAlD
Crizotinib—EPHB6—brain—intracranial aneurysm	0.00107	0.0025	CbGeAlD
Crizotinib—YES1—brain—intracranial aneurysm	0.00103	0.00242	CbGeAlD
Crizotinib—STK10—brain—intracranial aneurysm	0.00103	0.0024	CbGeAlD
Crizotinib—TAOK3—brain—intracranial aneurysm	0.00102	0.00239	CbGeAlD
Crizotinib—SRC—brain—intracranial aneurysm	0.000995	0.00233	CbGeAlD
Crizotinib—CSF1R—brain—intracranial aneurysm	0.000894	0.00209	CbGeAlD
Crizotinib—ABL1—cerebellum—intracranial aneurysm	0.00087	0.00203	CbGeAlD
Crizotinib—ABL1—brain—intracranial aneurysm	0.000706	0.00165	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—intracranial aneurysm	0.000382	0.000894	CbGeAlD
Crizotinib—ABCB1—midbrain—intracranial aneurysm	0.00035	0.000817	CbGeAlD
Crizotinib—ABCB1—cerebellum—intracranial aneurysm	0.00027	0.000632	CbGeAlD
Crizotinib—ABCB1—brain—intracranial aneurysm	0.00022	0.000513	CbGeAlD
Crizotinib—MAPK7—Signaling Pathways—NCF1—intracranial aneurysm	0.000202	0.000352	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CTSS—intracranial aneurysm	0.000199	0.000348	CbGpPWpGaD
Crizotinib—CDK7—Disease—NCF1—intracranial aneurysm	0.000199	0.000347	CbGpPWpGaD
Crizotinib—BLK—Immune System—CTSB—intracranial aneurysm	0.000199	0.000347	CbGpPWpGaD
Crizotinib—FGR—Immune System—CTSB—intracranial aneurysm	0.000198	0.000346	CbGpPWpGaD
Crizotinib—BLK—Immune System—NCF1—intracranial aneurysm	0.000198	0.000345	CbGpPWpGaD
Crizotinib—FGR—Immune System—NCF1—intracranial aneurysm	0.000197	0.000344	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CTSB—intracranial aneurysm	0.000196	0.000343	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—CCL2—intracranial aneurysm	0.000196	0.000343	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CTSK—intracranial aneurysm	0.000196	0.000342	CbGpPWpGaD
Crizotinib—JAK2—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000196	0.000342	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—NCF1—intracranial aneurysm	0.000195	0.000341	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CTSS—intracranial aneurysm	0.000195	0.00034	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TIMP1—intracranial aneurysm	0.000195	0.00034	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EDNRA—intracranial aneurysm	0.000195	0.00034	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CTSK—intracranial aneurysm	0.000194	0.00034	CbGpPWpGaD
Crizotinib—PTK2—Axon guidance—MMP2—intracranial aneurysm	0.000194	0.00034	CbGpPWpGaD
Crizotinib—EPHB6—Developmental Biology—MMP9—intracranial aneurysm	0.000194	0.000339	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CTSS—intracranial aneurysm	0.000193	0.000337	CbGpPWpGaD
Crizotinib—YES1—Immune System—CTSK—intracranial aneurysm	0.000193	0.000337	CbGpPWpGaD
Crizotinib—YES1—Axon guidance—MMP2—intracranial aneurysm	0.000192	0.000335	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CTSB—intracranial aneurysm	0.000191	0.000335	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EDNRA—intracranial aneurysm	0.00019	0.000333	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CTSS—intracranial aneurysm	0.000187	0.000327	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CTSK—intracranial aneurysm	0.000183	0.00032	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—NOS3—intracranial aneurysm	0.000182	0.000319	CbGpPWpGaD
Crizotinib—EPHA6—Developmental Biology—MMP9—intracranial aneurysm	0.000182	0.000319	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—AGER—intracranial aneurysm	0.000179	0.000314	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CTSK—intracranial aneurysm	0.000179	0.000313	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CTSK—intracranial aneurysm	0.000178	0.000311	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—AGER—intracranial aneurysm	0.000177	0.000309	CbGpPWpGaD
Crizotinib—TYK2—Axon guidance—MMP2—intracranial aneurysm	0.000176	0.000308	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—NOS3—intracranial aneurysm	0.000175	0.000306	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CTSK—intracranial aneurysm	0.000172	0.000301	CbGpPWpGaD
Crizotinib—LCK—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000171	0.000299	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TIMP1—intracranial aneurysm	0.00017	0.000298	CbGpPWpGaD
Crizotinib—SRC—EGF/EGFR Signaling Pathway—NOS3—intracranial aneurysm	0.000169	0.000296	CbGpPWpGaD
Crizotinib—EPHA2—Developmental Biology—MMP9—intracranial aneurysm	0.000168	0.000294	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—AGER—intracranial aneurysm	0.000168	0.000294	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CTSB—intracranial aneurysm	0.000168	0.000293	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—CCL2—intracranial aneurysm	0.000167	0.000292	CbGpPWpGaD
Crizotinib—TBK1—Immune System—AGER—intracranial aneurysm	0.000165	0.000289	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—AGER—intracranial aneurysm	0.000163	0.000285	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CTSB—intracranial aneurysm	0.000162	0.000283	CbGpPWpGaD
Crizotinib—PTK2—Immune System—NCF1—intracranial aneurysm	0.000161	0.000282	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CTSB—intracranial aneurysm	0.000161	0.000281	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—NCF1—intracranial aneurysm	0.00016	0.00028	CbGpPWpGaD
Crizotinib—YES1—Immune System—CTSB—intracranial aneurysm	0.00016	0.000279	CbGpPWpGaD
Crizotinib—YES1—Immune System—NCF1—intracranial aneurysm	0.000159	0.000278	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—CCL2—intracranial aneurysm	0.000159	0.000278	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—AGER—intracranial aneurysm	0.000158	0.000277	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SLC25A16—intracranial aneurysm	0.000156	0.000273	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTSS—intracranial aneurysm	0.000156	0.000273	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—NOS3—intracranial aneurysm	0.000156	0.000272	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTSS—intracranial aneurysm	0.000156	0.000272	CbGpPWpGaD
Crizotinib—TYK2—Disease—CST3—intracranial aneurysm	0.000155	0.000272	CbGpPWpGaD
Crizotinib—SRC—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000152	0.000265	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CTSB—intracranial aneurysm	0.000151	0.000265	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000151	0.000264	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TIMP1—intracranial aneurysm	0.000151	0.000264	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NCF1—intracranial aneurysm	0.000151	0.000263	CbGpPWpGaD
Crizotinib—JAK3—Immune System—AGER—intracranial aneurysm	0.000149	0.000261	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—NOS3—intracranial aneurysm	0.000149	0.000261	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NCF1—intracranial aneurysm	0.000149	0.00026	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—NOS3—intracranial aneurysm	0.000149	0.00026	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CTSB—intracranial aneurysm	0.000148	0.000259	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CTSB—intracranial aneurysm	0.000147	0.000257	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTSS—intracranial aneurysm	0.000146	0.000256	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NCF1—intracranial aneurysm	0.000146	0.000256	CbGpPWpGaD
Crizotinib—PTK2—Axon guidance—MMP9—intracranial aneurysm	0.000146	0.000255	CbGpPWpGaD
Crizotinib—YES1—Axon guidance—MMP9—intracranial aneurysm	0.000144	0.000252	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTSK—intracranial aneurysm	0.000144	0.000252	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTSK—intracranial aneurysm	0.000143	0.00025	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—MMP2—intracranial aneurysm	0.000143	0.00025	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CTSB—intracranial aneurysm	0.000142	0.000249	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—MMP2—intracranial aneurysm	0.000142	0.000249	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NCF1—intracranial aneurysm	0.000142	0.000248	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EDNRA—intracranial aneurysm	0.000141	0.000246	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—MMP9—intracranial aneurysm	0.00014	0.000245	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—CCL2—intracranial aneurysm	0.00014	0.000245	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—CCL2—intracranial aneurysm	0.00014	0.000245	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—MMP2—intracranial aneurysm	0.000139	0.000242	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—MMP2—intracranial aneurysm	0.000137	0.000239	CbGpPWpGaD
Crizotinib—TYK2—Disease—NCF1—intracranial aneurysm	0.000135	0.000236	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTSK—intracranial aneurysm	0.000135	0.000235	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—MMP2—intracranial aneurysm	0.000134	0.000234	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AGER—intracranial aneurysm	0.000133	0.000233	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NCF1—intracranial aneurysm	0.000133	0.000232	CbGpPWpGaD
Crizotinib—TYK2—Axon guidance—MMP9—intracranial aneurysm	0.000133	0.000232	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—CCL2—intracranial aneurysm	0.000133	0.000232	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AGER—intracranial aneurysm	0.000132	0.000231	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AGER—intracranial aneurysm	0.000131	0.00023	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AGER—intracranial aneurysm	0.000131	0.00023	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NCF1—intracranial aneurysm	0.000131	0.000229	CbGpPWpGaD
Crizotinib—BLK—Immune System—AGER—intracranial aneurysm	0.000128	0.000224	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTSS—intracranial aneurysm	0.000128	0.000224	CbGpPWpGaD
Crizotinib—FGR—Immune System—AGER—intracranial aneurysm	0.000128	0.000223	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—NOS3—intracranial aneurysm	0.000127	0.000223	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000126	0.000221	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—MMP2—intracranial aneurysm	0.000126	0.00022	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—NOS3—intracranial aneurysm	0.000126	0.00022	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EDNRA—intracranial aneurysm	0.000125	0.000219	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NCF1—intracranial aneurysm	0.000125	0.000219	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—NOS3—intracranial aneurysm	0.000125	0.000218	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—NOS3—intracranial aneurysm	0.000125	0.000218	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EDNRA—intracranial aneurysm	0.000124	0.000216	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AGER—intracranial aneurysm	0.000124	0.000216	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NCF1—intracranial aneurysm	0.000121	0.000212	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—CCL2—intracranial aneurysm	0.000121	0.000212	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—MMP9—intracranial aneurysm	0.000119	0.000209	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTSB—intracranial aneurysm	0.000119	0.000208	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTSB—intracranial aneurysm	0.000119	0.000207	CbGpPWpGaD
Crizotinib—LYN—Immune System—NCF1—intracranial aneurysm	0.000118	0.000207	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000118	0.000207	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—NOS3—intracranial aneurysm	0.000118	0.000207	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC25A16—intracranial aneurysm	0.000118	0.000206	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTSK—intracranial aneurysm	0.000118	0.000206	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NCF1—intracranial aneurysm	0.000118	0.000206	CbGpPWpGaD
Crizotinib—JAK2—Disease—CST3—intracranial aneurysm	0.000118	0.000206	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—CCL2—intracranial aneurysm	0.000117	0.000205	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000115	0.0002	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000115	0.0002	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTSS—intracranial aneurysm	0.000113	0.000198	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTSB—intracranial aneurysm	0.000111	0.000195	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NCF1—intracranial aneurysm	0.000111	0.000194	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AGER—intracranial aneurysm	0.000108	0.000189	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—NOS3—intracranial aneurysm	0.000108	0.000189	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—MMP9—intracranial aneurysm	0.000107	0.000188	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—MMP9—intracranial aneurysm	0.000107	0.000187	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—CCL2—intracranial aneurysm	0.000106	0.000185	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AGER—intracranial aneurysm	0.000105	0.000183	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTSK—intracranial aneurysm	0.000104	0.000183	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—MMP9—intracranial aneurysm	0.000104	0.000182	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NCF1—intracranial aneurysm	0.000104	0.000182	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP2—intracranial aneurysm	0.000104	0.000181	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ASAH1—intracranial aneurysm	0.000104	0.000181	CbGpPWpGaD
Crizotinib—LCK—Disease—CST3—intracranial aneurysm	0.000103	0.00018	CbGpPWpGaD
Crizotinib—YES1—Immune System—AGER—intracranial aneurysm	0.000103	0.00018	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—MMP9—intracranial aneurysm	0.000103	0.00018	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NCF1—intracranial aneurysm	0.000103	0.00018	CbGpPWpGaD
Crizotinib—JAK2—Disease—NCF1—intracranial aneurysm	0.000102	0.000179	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP2—intracranial aneurysm	0.000102	0.000178	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP2—intracranial aneurysm	0.000102	0.000177	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—MMP9—intracranial aneurysm	0.000101	0.000176	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—MMP9—intracranial aneurysm	0.0001	0.000175	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—MMP9—intracranial aneurysm	0.0001	0.000175	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EDNRA—intracranial aneurysm	9.84e-05	0.000172	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AGER—intracranial aneurysm	9.78e-05	0.000171	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTSB—intracranial aneurysm	9.76e-05	0.000171	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NCF1—intracranial aneurysm	9.74e-05	0.00017	CbGpPWpGaD
Crizotinib—LCK—Immune System—NCF1—intracranial aneurysm	9.71e-05	0.00017	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EDNRA—intracranial aneurysm	9.7e-05	0.00017	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—CCL2—intracranial aneurysm	9.59e-05	0.000168	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AGER—intracranial aneurysm	9.58e-05	0.000167	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP2—intracranial aneurysm	9.54e-05	0.000167	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AGER—intracranial aneurysm	9.49e-05	0.000166	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—MMP9—intracranial aneurysm	9.48e-05	0.000166	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—MMP9—intracranial aneurysm	9.46e-05	0.000165	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NCF1—intracranial aneurysm	9.46e-05	0.000165	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—NOS3—intracranial aneurysm	9.45e-05	0.000165	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—CCL2—intracranial aneurysm	9.38e-05	0.000164	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—NOS3—intracranial aneurysm	9.37e-05	0.000164	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—NOS3—intracranial aneurysm	9.33e-05	0.000163	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EDNRA—intracranial aneurysm	9.2e-05	0.000161	CbGpPWpGaD
Crizotinib—SRC—Disease—CST3—intracranial aneurysm	9.13e-05	0.00016	CbGpPWpGaD
Crizotinib—LCK—Disease—NCF1—intracranial aneurysm	8.97e-05	0.000157	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EDNRA—intracranial aneurysm	8.93e-05	0.000156	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—NOS3—intracranial aneurysm	8.77e-05	0.000153	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—MMP9—intracranial aneurysm	8.67e-05	0.000152	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTSB—intracranial aneurysm	8.64e-05	0.000151	CbGpPWpGaD
Crizotinib—SRC—Immune System—NCF1—intracranial aneurysm	8.6e-05	0.00015	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—NOS3—intracranial aneurysm	8.54e-05	0.000149	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—NOS3—intracranial aneurysm	8.36e-05	0.000146	CbGpPWpGaD
Crizotinib—CDK7—Disease—NOS3—intracranial aneurysm	8.24e-05	0.000144	CbGpPWpGaD
Crizotinib—SRC—Disease—NCF1—intracranial aneurysm	7.94e-05	0.000139	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ASAH1—intracranial aneurysm	7.82e-05	0.000137	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP9—intracranial aneurysm	7.79e-05	0.000136	CbGpPWpGaD
Crizotinib—LYN—Immune System—AGER—intracranial aneurysm	7.69e-05	0.000134	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NOS3—intracranial aneurysm	7.68e-05	0.000134	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP9—intracranial aneurysm	7.66e-05	0.000134	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NCF1—intracranial aneurysm	7.66e-05	0.000134	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AGER—intracranial aneurysm	7.65e-05	0.000134	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP9—intracranial aneurysm	7.63e-05	0.000133	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MMP9—intracranial aneurysm	7.58e-05	0.000133	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—CCL2—intracranial aneurysm	7.45e-05	0.00013	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP2—intracranial aneurysm	7.4e-05	0.000129	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC25A16—intracranial aneurysm	7.27e-05	0.000127	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EDNRA—intracranial aneurysm	7.23e-05	0.000126	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AGER—intracranial aneurysm	7.19e-05	0.000126	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP9—intracranial aneurysm	7.17e-05	0.000125	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NCF1—intracranial aneurysm	7.17e-05	0.000125	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CCL2—intracranial aneurysm	6.93e-05	0.000121	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MMP9—intracranial aneurysm	6.86e-05	0.00012	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NOS3—intracranial aneurysm	6.8e-05	0.000119	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EDNRA—intracranial aneurysm	6.77e-05	0.000118	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MMP9—intracranial aneurysm	6.71e-05	0.000117	CbGpPWpGaD
Crizotinib—LCK—Immune System—AGER—intracranial aneurysm	6.3e-05	0.00011	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NCF1—intracranial aneurysm	6.28e-05	0.00011	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NOS3—intracranial aneurysm	6.18e-05	0.000108	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCL2—intracranial aneurysm	6.18e-05	0.000108	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCL2—intracranial aneurysm	6.09e-05	0.000106	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EDNRA—intracranial aneurysm	5.93e-05	0.000104	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCL2—intracranial aneurysm	5.83e-05	0.000102	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCL2—intracranial aneurysm	5.65e-05	9.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CCL2—intracranial aneurysm	5.65e-05	9.87e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NOS3—intracranial aneurysm	5.6e-05	9.79e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—AGER—intracranial aneurysm	5.58e-05	9.75e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP9—intracranial aneurysm	5.56e-05	9.72e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NCF1—intracranial aneurysm	5.56e-05	9.72e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NOS3—intracranial aneurysm	5.51e-05	9.63e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NOS3—intracranial aneurysm	5.43e-05	9.49e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EDNRA—intracranial aneurysm	5.25e-05	9.18e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NOS3—intracranial aneurysm	5.19e-05	9.08e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NOS3—intracranial aneurysm	5.04e-05	8.8e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP9—intracranial aneurysm	4.96e-05	8.66e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCL2—intracranial aneurysm	4.85e-05	8.47e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ASAH1—intracranial aneurysm	4.82e-05	8.42e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCL2—intracranial aneurysm	4.78e-05	8.36e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL2—intracranial aneurysm	4.53e-05	7.93e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—intracranial aneurysm	4.42e-05	7.72e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL2—intracranial aneurysm	4.4e-05	7.7e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—intracranial aneurysm	4.35e-05	7.61e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—intracranial aneurysm	4.32e-05	7.55e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—intracranial aneurysm	4.26e-05	7.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—intracranial aneurysm	4.25e-05	7.42e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—intracranial aneurysm	4.17e-05	7.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—intracranial aneurysm	4.04e-05	7.07e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—intracranial aneurysm	4.04e-05	7.06e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—intracranial aneurysm	3.92e-05	6.86e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—intracranial aneurysm	3.72e-05	6.5e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—intracranial aneurysm	3.56e-05	6.23e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—intracranial aneurysm	3.47e-05	6.06e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—intracranial aneurysm	3.42e-05	5.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—intracranial aneurysm	3.34e-05	5.83e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—intracranial aneurysm	3.29e-05	5.76e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—intracranial aneurysm	3.24e-05	5.67e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—intracranial aneurysm	3.18e-05	5.55e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—intracranial aneurysm	3.15e-05	5.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—intracranial aneurysm	2.97e-05	5.2e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—intracranial aneurysm	2.92e-05	5.11e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—intracranial aneurysm	2.6e-05	4.55e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—intracranial aneurysm	2.59e-05	4.52e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—intracranial aneurysm	2.55e-05	4.46e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—intracranial aneurysm	2.39e-05	4.17e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—intracranial aneurysm	2.31e-05	4.03e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—intracranial aneurysm	2.16e-05	3.78e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—intracranial aneurysm	2.09e-05	3.65e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—intracranial aneurysm	1.85e-05	3.23e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—intracranial aneurysm	1.63e-05	2.85e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—intracranial aneurysm	1.01e-05	1.76e-05	CbGpPWpGaD
